Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
ROSELAND, N.J., Feb. 22, 2018 -- Novo Nordisk announced today the successful completion of the first phase 3a trial, PIONEER 1, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere Technologies, Inc.’s (“Emisphere” or the “Company”) proprietary Eligen® Technology.
A copy of Novo Nordisk’s announcement can be found at https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2170941.html
About Emisphere
Emisphere is a drug delivery company that utilizes its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere is currently partnered with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, please visit the Company's website at www.emisphere.com.
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development activities and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the Company's business development activities and the sufficiency of the Company's cash position. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including , but not limited to, the sufficiency of Emisphere’s cash position, the success of our and our partner’s development and commercialization efforts, and our ability to successfully partner our Eligen® Technology.
CONTACT: Philip Nikolayuk, Finance Director & IR 973.532.8014 [email protected]
